Riskpilot← Back to searchSign inGet full accessFrey SurgiBioMed AB
ABActiveOrg 5594004185Skördevägen 51Hospital activities · NACE 8610Est. 20220 employees
Revenue 2025
SEK 55K
+242% vs 2024
EBITDA margin
1.9%
+102% vs 2024
Equity ratio
92.0%
Financial strength
Net profit 2025
SEK 1K
+102% vs 2024
| Revenue | SEK 55K | +242% |
| EBITDA | SEK 1K | +102% |
| Net profit | SEK 1K | +102% |
| Total assets | SEK 222K | -1% |
| Equity | SEK 204K | +1% |
| Employees | 0 | — |
Legal name
Frey SurgiBioMed AB
Org number
5594004185
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
7 oktober 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva konsultverksamhet inom urologi och kirurgi med särskild hänsyn till robotassisterad kirurgi och utbildning inom operativ verksamhet inom Sverige och utomlands. Företaget kommer också bedriva verksamhet inom öppen och sluten sjukvård. Utöver detta konsultuppdrag inom labverksamheten (kemiska analyser) och även översättningstjänster.
Address
Skördevägen 51
Email
janusz.frey@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 411 | 16 | 55 |
| Staff expenses | — | — | — |
| EBITDA | 296 | −57 | 1 |
| Depreciation & amort. | — | — | — |
| EBIT | 296 | −57 | 1 |
| Net financials | 0 | 0 | −0 |
| Profit before tax | 297 | −57 | 1 |
| Tax | −61 | — | — |
| Net profit | 235 | −57 | 1 |
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 322 | 224 | 222 |
| Equity | 260 | 203 | 204 |
| Long-term debt | — | — | — |
| Short-term debt | 62 | 21 | 18 |
| Total debt | 62 | 21 | 18 |
EBITDA margin
1.9%
This company
15.8%
Market median
-88% vs market
20232025
Equity ratio
92.0%
This company
38.2%
Market median
+141% vs market
20232025
Return on equity
0.5%
This company
18.4%
Market median
-97% vs market
20232025
Net profit margin
1.9%
This company
8.1%
Market median
-77% vs market
20232025
Asset turnover
0.25×
This company
1.12×
Market median
-78% vs market
20232025
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20232025
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Former (6) | ||
| Board of Directors | 2022 – 2022 | |
| Chairman | 2022 – 2022 | |
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Frey SurgiBioMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Janusz Krzysztof Frey | Board of Directors | 0 companies |
| Anna-Klara Hansson | Board of Directors | 0 companies |
| Yngve Erik Oskar Månsson | Chairman | 0 companies |
| Aleksandra Grazyna Rothe-Frey | Deputy Board Member | 0 companies |
| Nathalie Viktoria Louise Fernström | Chairman | 0 companies |
| Caroline Linnea Christina Säisä | Board of Directors | 0 companies |
| Maria Magdalena Frey | Deputy Board Member | 0 companies |
| Pär Daniel Roger Johansson | Board of Directors | 0 companies |
| John Simon Jonsson | Board of Directors | 0 companies |